ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, has taken a significant step in its partnership with AiBtl BioPharma Inc. by converting a $100,000 convertible note into 10,000 shares of common stock at a conversion price of $10 per share. This move, supported by an independent third-party valuation, underscores ABVC's confidence in AiBtl's valuation and its commitment to the biopharmaceutical firm's success. Furthermore, ABVC has announced its intention to invest up to $20 million in AiBtl over time, reinforcing its position as a lead strategic investor.
The additional funds are expected to enable AiBtl to meet its licensing obligations and collaborate with global pharmaceutical partners to accelerate the Phase III development of its CNS drug candidates, ABV-1504 and ABV-1505. These candidates are part of a licensing agreement that includes equity, milestone payments, and royalties, potentially benefiting ABVC and its subsidiary BioLite with up to 46 million shares of AiBtl common stock, $7 million in cash milestone payments, and future sales-based royalties.
Dr. Uttam Patil, ABVC Chief Executive Officer, emphasized the company's dual role as both a licensing partner and anchor investor, highlighting the investment's role in strengthening AiBtl's pipeline advancement and ABVC's potential to benefit from future revenues. This strategic investment not only supports AiBtl's development of botanical-based therapeutic candidates for CNS disorders but also aligns with ABVC's capital-light strategy of investing in innovative partners through a combined licensing and equity model.
The collaboration between ABVC and AiBtl represents a significant development in the biopharmaceutical industry, particularly in the treatment of CNS disorders such as major depressive disorder and attention deficit hyperactivity disorder. By leveraging traditional botanical knowledge and modern clinical research, AiBtl aims to introduce novel therapeutic solutions, with a strategic focus on the Asia-Pacific markets and potential global partnerships. This investment could pave the way for groundbreaking treatments in the CNS space, offering hope to patients worldwide.
